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Abstract 
Review on PTPRA, with data on DNA/RNA 
expression, on the protein encoded, and the 
functional importance of the gene. 
Identity 
Other names: HEPTP, HLPR, HPTPA, 
HPTPalpha, LRP, PTPA, PTPRL2, R-PTP-alpha, 
RPTPA 
HGNC (Hugo): PTPRA 
Location: 20p13 
DNA/RNA 
Description 
Human PTPRA is located at Chromosome 20: 
2844830-3019722 bp.  
Its Entrez gene ID is 5786 (NCBI) or 9664 
(HGNC).  
PTPRA consists of 21 coding exons (protein 
isoform 1) or 20 coding exons (protein isoform 2). 
82 organisms have orthologs with human gene 
PTPRA.  
The PTPRA gene is conserved across species 
including chimpanzee, Rhesus monkey, dog, cow, 
mouse, rat, chicken, zebrafish, and C. elegans. 
Transcription 
Three transcript variants encoding different 
isoforms have been found for PTPRA gene. 
Transcript variant 1 (NM_002836.3) represents the 
longest transcript and encodes the longer isoform1 
including 802 aa residues. Transcript variant 2 
(NM_080840.2) contains an alternate 5' UTR exon 
which is different from transcript variant 1, and 
lacks exons one to five and coding exon ten, when 
compared to variant 1. Transcript variant 3 
(NM_080841.2) contains an additional exon within 
the 5' UTR, when compared to variant 2. Transcript 
variant 2 and transcript variant 3 encode the short 
isoform 2. Isoform 2 lacks a 9 aa internal segment, 
because exon ten missing, compared to Isoform 1. 
It is known that the expression of RPTPa mRNA is 
increased by 2 to 10-fold in 70% (10 of 14) of late-
stage colon tumors compared to normal colonic 
mucosa (Tabiti et al., 1995). Another study 
demonstrated that RPTPa mRNA was increased in 
29% (15 of 51) of primary breast carcinomas and 
correlated with its protein overexpression (Ardini et 
al., 2000). Recently, PTPRA mRNA splice mutants 
were described from Chinese colon, breast, and 
liver tumors (Huang et al., 2011). 
Pseudogene 
One pseudogene (ID: PGOHUM00000236674) for 
PTPRA described on the website Pseudogenes.org. 
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Schematic depiction of human gene PTPRA (upper panel), derived alternative transcripts (middle panel) and 
corresponding protein isoforms (lower panel). Arrows in the upper panel indicate the three distinct transcriptional start sites 
within chromosome 20p13. 28 exon numbers according to transcript variant 1 (NM_002836.3) are indicated above the 
corresponding boxes. In the middle panel the build-up of the three different PTPRA transcripts, deduced based on cDNA 
deposits in public databases, is depicted. Transcript variant 1 (NM_002836.3) represents the longest transcript and encodes the 
longer isoform 1. Transcript variant 2 (NM_080840.2) contains an alternate 5' UTR exon which is different from transcript variant 
1, and lacks coding exons one to five and exon ten, when compared to variant 1. Transcript variant 3 (NM_080841.2) contains 
an additional exon within the 5' UTR, and lacks an coding exon and exon one to five, when compared to variant 1. Transcript 
variant 2 and transcript variant 3 encode the short isoform 2. The N-terminal, the protein domain reflects the signal peptide (SP). 
The transmembrane spanning regions (TM) and protein tyrosine phosphatase catalytic domain (D1 and D2) are shown 
respectively. Isoform 2 lacks a 9 aa internal segment, because of exon ten missing, compared to Isoform 1. 
 
Protein 
Description 
The protein encoded by PTPRA gene is a member 
of the protein tyrosine phosphatase (PTP) family. 
This PTP contains an extracellular domain, a single 
transmembrane segment and two tandem 
intracytoplasmic catalytic domains, and thus 
represents a receptor-type PTP. Three alternatively 
spliced variants of this gene are well known to 
encode two distinct isoforms differing only in their 
extracellular region. The shorter form, expressed in 
most tissues, has 793 aa of which 123 are 
extracellular. The longer form, RPTPa802, has nine 
extra amino acids located just before the 
transmembrane region and is expressed only in a 
few tissues, especially in brain. It is noted that 
extensive N- and O-linked glycosylation of RPTPa 
gives rise to a mature 130 kD form of the protein 
(Daum et al., 1994). 
Expression 
PTPRA gene was originally isolated by PCR-based 
PTP identification and cloning from several groups 
(Sap et al., 1990; Kaplan et al., 1990; Matthews et 
al., 1990). The protein, RPTPa, is a widely 
distributed transmembrane molecule that is 
particularly highly expressed in the brain and 
kidney (Sap et al., 1990). RPTPa is highly 
expressed in the developing central and peripheral 
nervous system of mouse, especially in the dorsal 
root ganglia, cranial ganglia and adrenal gland (den 
Hertog et al., 1996). During chicken development, 
chicken RPTPa (ChPTPa) is expressed in pre-
migratory and migrating granule cells, and in 
Bergmann glia and their radial processes as 
determined by in situ hybridization and 
immunostaining (Fang et al., 1996). Taken together, 
these studies demonstrate that RPTPa is highly 
expressed in the developing brain of various species 
(Shock et al., 1995; Yang and Friesel, 1998; den 
Hertog et al., 1999). 
Localisation 
Membrane. A typical single-pass type I membrane 
protein. 
Function 
Generally, RPTPa has been shown to 
dephosphorylate and activate Src family kinases 
(SFKs), and is implicated in the regulation of 
integrin signaling, cell adhesion and proliferation. 
Studies involving overexpression of RPTPa were 
the first to demonstrate that PTP can 
dephosphorylate tyrosine 527 of Src and activate c-
Src in vivo and in vitro. This activation causes 
cellular transformation (Zheng et al., 1992). 
Dephosphorylation of tyrosine 527 of c-Src in 
RPTPa overexpressing P19 embryonal carcinoma 
cells activates c-Src and induces neuronal 
differentiation (den Hertog et al., 1993). This 
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observation has been independent validated in 
studied involving RPTPa knockout mice that 
exhibit a dramatic decrease (50-70%) in c-Src 
activity in the brain (Ponniah et al., 1999; Su et al., 
1999).  
In addition to Src, RPTPa regulates other Src 
family kinases.  
As an example, Fyn dephosphorylation and 
activation is observed in cells co-expressing RPTPa 
and Fyn (Bhandari et al., 1998).  
Additionally, dephosphorylation of c-Src, Fyn and 
Yes, but not Lyn, was observed in A431 cells 
expressing RPTPa (Harder et al., 1998), indicating 
some degree of specificity of RPTPa.  
It is noteworthy that there is no evidence of gross 
physical abnormalities in the RPTPa-deficient mice, 
indicating that RPTPa is not essential for 
embryonic development.  
One explanation is that certain functions of RPTPa 
are compensated for by other PTPs in mice 
deficient in RPTPa (Pallen, 2003).  
RPTPa is involved in promoting integrin signaling 
through activation of SFKs.  
An earlier study shows that c-Src activation by 
RPTPa can increase the association of c-Src with 
focal adhesion kinase (FAK), and enhance tyrosine 
phosphorylation of the Src/FAK substrate paxillin 
(Harder et al., 1998). Recently, Sun et al. described 
a novel molecular complex of RPTPa-BCAR3-Cas-
Src that is important in integrin signaling (Sun et 
al., 2012). This complex forms in response to 
RPTPaTyr789 phosphorylation and mediates Cas 
localization to focal adhesions and Cas downstream 
signaling to promote cell migration (Sun et al., 
2012).  
More recently, Cheng et al. identified two roles of 
Grb2 in integrin signaling: one as a regulator of 
paxillin stability and upstream promoter of 
FAKTyr397 phosphorylation that is required for 
Src-FAK complex activation and another as an 
essential coordinator of RPTPa and activation of 
the Src-FAK interaction thus enabling the 
phosphorylation of RPTPaTyr789 (Cheng et al., 
2014). 
Mutations 
Note 
Huang et al. sequence RPTPa cDNAs from five 
types of Chinese human tumors and paired normal 
samples. They observed three sequences encoding 
truncated proteins, designated RPTPa245, 
RPTPa445, or RPTPa652, lacking the D1 domain 
or both the D1 and D2 domains. One mutant, 
RPTPa245, widely expressed in colon, breast, and 
liver tumors from individuals of Chinese origin, can 
form an RPTPa-RPTPa245 heterodimer and 
activate c-Src. (Huang et al., 2011). 
Implicated in 
Breast cancer 
Note 
It is clear that RPTPa functions as an activator of c-
Src family kinases, and thus was considered to be 
an oncogene. However, the first study on human 
breast tumors by Ardini et al. revealed an 
unexpected and interesting role of RPTPa. RPTPa 
protein levels are found significantly overexpressed 
in 29% of 51 samples. High RPTPa protein levels 
correlated with low tumor grade and positive 
estrogen receptor status. 
Overexpression of RPTPa in MCF-7 breast cancer 
cells (ER+) resulted in growth inhibition while 
activating c-Src (Ardini et al., 2000). In a later 
study, Zheng reported that knockdown of RPTPa 
and c-Src using RNAi induced apoptosis in 
estrogen receptor-negative breast cancer cells, but 
not in immortalized noncancerous breast cells and 
ER-positive breast cancer cells (including MCF-7). 
It is noted by Zheng that correlation between ER 
status and c-Src/RPTPa dependence in breast 
cancer may be important for planning therapeutic 
strategy (Zheng et al., 2008). Recently, Wang J and 
colleagues reported that EGF-induced RPTPa 
phosphorylation at Ser180 and Ser204 in BT-20 
and SKBR3 breast cancer cell lines results in 
increased c-Src kinase activity, due to a decrease in 
RPTPa binding with Grb2 and an increase in 
RPTPa binding with c-Src. These observations 
reveal novel aspects of integration of an 
EGF/PKC/RPTPa/Src pathway in breast cancer cell 
lines (Wang et al., 2013). Currently, Meyer et al. 
demonstrate that RPTPa functions as a positive 
mediator of tumor initiation and maintenance in 
both HER2/Neu-positive breast tumors (Meyer et 
al., 2014). 
Colorectal cancer 
Note 
The first report correlation with RPTPa and colonic 
tumors was reported by Tabiti et al. in 1995. They 
quantified mRNA levels of RPTPa from 14 colon 
carcinomas and compared these levels to adjacent 
healthy colon mucosa. They observed a 2 to 10-fold 
increase in mRNA levels in advanced (Dukes' stage 
D) carcinoma. Another study from Zheng et al. 
reported that RNAi knockdown of RPTPa reduced 
c-Src kinase activity in several colon cancer cell 
lines (HCT-15, HCT-116 and HT-29), which 
suppresses anchorage-independent growth and 
induces apoptosis (Zheng et al., 2008). Recently, 
tissue-arrays containing 50 colorectal cancer 
specimens and 10 normal colon samples were 
analysed by immunohistochemistry for RPTPa 
expression. In normal tissue samples, RPTPa 
expression was restricted to smooth muscle cells. 
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None of the normal colonocyte expressed RPTPa in 
measurable quantities. However, over 70% of the 
colon cancer samples demonstrated expression of 
RPTPa (Krndija et al., 2010). These data provide 
evidence for an oncogenic role of RPTPa in 
colorectal cancer. 
Gastric cancer 
Note 
To date, only one study has revealed an association 
between RPTPa expression and gastric cancer. 
RPTPa expression is observed in 44% of gastric 
samples and was the most widely expressed of the 
five PTPs. Several clinicopathological features 
were significantly linked with the expression of 
RPTPa, including gross appearance, 
lymphovascular invasion, lymph node metastasis, 
liver metastasis and peritoneal dissemination. (Wu 
et al., 2006). 
Oral squamous cell carcinoma 
(OSCC) 
Note 
In an earlier study, Berndt et al. evaluated RPTPa 
expression in 12 oral squamous cell carcinoma 
(OSCC) samples. Interestingly, not only the tumor 
cells but also the stromal fibro/myofibroblasts as 
well as inflammatory cells account for RPTPa 
expression in OSCC. In particular, immunostaining 
revealed a predominantly intracellular pattern of 
RPTPa expression, which may be due to an 
incompletely glycosylated form (Berndt et al., 
1999) and/or to proteolytic cleavage of RPTPa in 
vivo (Gil-Henn et al., 2001). 
Diffuse large B-cell lymphoma 
Cytogenetics 
A dup(20)(p13p13) was found in a case of diffuse 
large B-cell lymphoma (Morin et al., 2013). 
Hybrid/Mutated gene 
TMC2/PTPRA. 
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